Bassem Elmankabadi, MD, ABWS

Title: Executive Medical Director, Clinical Development (Fibrosis/Oncology)

Organization: FibroGen

Bio: Bassem Elmankabadi, M.D. is the clinical development lead for FibroGen DMD program. Bassem has held multiple clinical leadership roles in Amgen oncology and nephrology. Prior to joining FibroGen in Feb 2018, Bassem was a Senior Medical director, responsible for Imlygic and Prasabiv programs at Amgen. Bassem experience also including registration phase 2 and phase 3 clinical trials required for NDA and BLA submissions for both PARSABIV and Imlygic in US and in EU. Prior to Amgen, Bassem was a Medical Director, clinical instructor at UCLA for KRAS oncogene program, FOLFOX/FOLFIRI for refractory colorectal cancer. Bassem is a board certified minimally invasive surgeon, he completed his surgical training at Brooklyn hospital center, affiliated with Icahn School of Medicine at Mount Sinai and his internship and trauma rotation at SUNY Downstate, in Brooklyn New York. Bassem received his M.D. degree followed by master degree (MSc) in Ophthalmology from University of Cairo, in Cairo Egypt.

FibroGen

FibroGen Industry Presentation

FibroGen accelerates the delivery of innovative treatments that operate at the cutting edge of cancer research. Our teams have identified and are developing potential first-in-class medicines for the treatment of life-threatening conditions such as metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and chemotherapy-induced anemia (CIA). We are keenly focused on leveraging the body’s natural pathways to treat cancer and its related conditions.

Bassem Elmankabadi, MD, ABWS

Executive Medical Director, Clinical Development (Fibrosis/Oncology)

FibroGen